Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.

There is provided a liposome complex for cancer treatment including a novel CD47 binder and a polynucleotide, in which the liposome complex has a mechanism to kill cancer cells by maximizing the metabolic vulnerability of cancer cells. There is also provided a complex for cancer treatment, which includes a polynucleotide encoding an amino acid sequence represented by SEQ ID NO: 3, a liposome in which the polynucleotide is captured, and a binder which is conjugated to the liposome, binds to CD47 overexpressed in cancer cells, and includes an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2.

Self-preserving topical pharmaceutical compositions comprising diethylene glycol monoethyl ether (DEGEE) maintained at an acidic pH. The pH of the formulation can be maintained at a pH of less than 6.3, or alternatively less than 6.0. The topical pharmaceutical compositions disclosed herein are self-preserving and can satisfy European Pharmacopeia Efficacy of Antimicrobial Preservation Criteria A without the addition of a traditional antimicrobial preservative. Certain pharmaceutical composition further comprise an emulsifier blend of cetearyl alcohol, dicetyl phosphate, and ceteth-10 phosphate, which is manufactured by Croda under the tradename Crodafos™ CES.

The disclosure provides oligonucleotide-ligand conjugates to facilitate the systemic delivery of oligonucleotides designed to prevent, limit or modulate the expression of mRNA molecules. The conjugates comprise nucleotides which are linked to lipid conjugate moieties or adamantyl groups.

The present invention provides compounds suitable for use in the treatment of conditions where it is beneficial to halt bone loss and kill cancer cells, particularly in metastases to and primary tumors in the bone and surrounding tissues. Consequently the present invention provides compounds comprising a bisphosphonate moiety linked to a phytochemical, pharmaceutical compositions thereof and methods of treatment of bone diseases and/or proliferative disorders.

Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.

The present invention provides a method for reducing the protein aggregation by adjusting the pH below 6.0 of liquid formulation comprising the antibody or fusion protein. The present invention also provides methods for storing the pre-formulation for longer period without using any sugar or additives which can be utilized for preparation of liquid or lyophilized formulation.

The present invention provides phosphorylcholine conjugates and pharmaceutical compositions comprising same for the prevention or treatment of autoimmune diseases. In particular, the conjugates of the present invention are effective in treating autoimmune diseases associated with pathological inflammation.

Self-preserving topical pharmaceutical compositions comprising diethylene glycol monoethyl ether (DEGEE) maintained at an acidic pH. The pH of the formulation can be maintained at a pH of less than 6.3, or alternatively less than 6.0. The topical pharmaceutical compositions disclosed herein are self-preserving and can satisfy European Pharmacopeia Efficacy of Antimicrobial Preservation Criteria A without the addition of a traditional antimicrobial preservative. Certain pharmaceutical composition further comprise an emulsifier blend of cetearyl alcohol, dicetyl phosphate, and ceteth-10 phosphate, which is manufactured by Croda under the tradename Crodafos™ CES.

A long-lasting hydrogel for use against drug-resistant bacteria, and a preparation method and use thereof are provided. In the present disclosure, polyvinyl alcohol (PVA) is mainly adopted as a matrix, and phytic acid and honey including glucose and fructose are added to modify the PVA to obtain the hydrogel. During preparation of the antimicrobial hydrogel, no toxic chemical crosslinking agent or initiator is added, and the antimicrobial hydrogel is mainly obtained by crosslinking PVA, phytic acid, and monosaccharides through ester bonds, hydrogen bonds, and electrostatic adsorption. In addition, the hydrogel obtained by adding phytic acid and honey to the PVA matrix exhibits a significant long-lasting antimicrobial effect for Staphylococcus aureus (S aureus), drug-resistant S. aureus, and Pseudomonas aeruginosa (P. aeruginosa), and the antimicrobial effect can last for about 3 months.